abstract |
The invention relates to peptides derived from GLP-1 (Glucagon-like Peptide 1) and exendin-3 and/or exendin-4, which bind to GLP-1 receptors and may be used either marked or unmarked for the production of a means for diagnosis and therapy of benign and pernicious diseases in which GLP-1 receptor expression plays a role. |